Physician’s Weekly – 02/27/2023 – The following article is a summary of “Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial,” published in the January 2023 issue of Journal of Clinical Oncology by Dimopoulos, et al .
Patients with relapsed/refractory multiple myeloma (RRMM) who had previously received lenalidomide and a proteasome inhibitor were treated in the phase II ELOQUENT-3 trial, and the combination of elotuzumab and pomalidomide/dexamethasone (EPd) significantly improved progression-free survival (PFS) compared to pomalidomide (PI).
Patients with RRMM who had had ≥2 prior lines of treatment had disease resistance to the last medication and either relapsed or resistant to lenalidomide and a PI, were randomized at random (1:1) to receive EPd or Pd. PFS was the main outcome, in the opinion of the investigator. The secondary endpoints ORR and OS were intended to be examined hierarchically.
About 117 patients were randomly divided into EPd (n = 60) and Pd (n = 57). Around 37 (61.7%) and 41 (74.5%) of the treated patients (EPd 60, Pd 55) passed away, with illness progression (EPd 41.7%, Pd 49.1%) accounting for the majority of fatalities. Compared to Pd (17.4 [13.8 to 27.7] months), the median (95% CI) OS was considerably better with EPd (29.8 [22.9 to 45.7] months), with a hazard ratio of 0.59 (95% CI, 0.37 to 0.93; P= .0217). Most patient subgroups who received EPd saw an OS advantage. No new safety signals were found, and the EPd’s safety profile was consistent with earlier studies.
When compared to Pd, EPd showed a statistically significant improvement in overall survival (OS) for patients with RRMM who had previously taken lenalidomide and a PI and whose illness had not responded to any treatment. ELOQUENT-3 was the first randomized study of a triplet regimen using a monoclonal antibody and Pd to increase both PFS and OS in the situation significantly.
- Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial. Dimopoulos MA, et al. J Clin Oncol. 2023 Jan 20;41(3):568-578.
Originally Published By Physician’s Weekly. Reused by Medicom Medical Publishers with permission.
©2023 Physician’s Weekly. All rights reserved. No works may be reproduced without expressed written consent from Physician’s Weekly. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by Physician’s Weekly.
« CAR T cells rise to the front in multiple myeloma Next Article
Positive results for hereditary transthyretin-mediated amyloid polyneuropathy »